Artificially Inflated Insulin Prices
Over the past two decades, insulin prices have surged more than 1,200% — despite no significant changes to the medication itself. This dramatic increase has raised serious concerns about the unethical, profit-driven practices of manufacturers.
While it costs just $2 to $4 to produce a vial of insulin, some pharmaceutical companies raised the price to over $250 per vial. Many patients with diabetes need several vials each month.
For years, American consumers were overcharged for insulin, paying more than 9 times what people in other high-income countries paid for the same drug. This crisis made insulin unaffordable for millions.
With over 45 years of experience taking on powerful companies, Sokolove Law has a history of successfully securing justice for those harmed by corporate wrongdoing.
Get the Help You Deserve
Our experienced attorneys may be able to help communities seek justice from an insulin price lawsuit. Get started now with a free case review.
Why Is Insulin Overpriced?
Pharmacy benefit managers (PBMs) and drug manufacturers are the two groups largely responsible for driving up the price of insulin:
- PBMs act as intermediaries between drug manufacturers and insurance companies, negotiating prices and rebates that often lead to inflated costs for consumers.
- Drug manufacturers prioritize profit margins over patient access, focusing on maximizing rebate agreements with PBMs instead of providing affordable insulin options.
As PBMs and manufacturers collected billions, 1 out of every 4 Americans were left unable to afford insulin, according to the Federal Trade Commission.
Insulin Overpricing Lawsuits & Corporate Accountability
The insulin overpricing lawsuit seeks to hold key players in the pharmaceutical industry accountable for their roles in inflating the cost of this essential medication.
Lawsuits have been filed against insulin drug manufacturers Eli Lilly, Sanofi, and Novo Nordisk as well as PBMs Caremark Rx, Express Scripts, and OptumRx, who administer approximately 80% of medications in the U.S.
Multiple state and local governments are investigating insulin manufacturers and PBMs for unfair pricing practices that made it increasingly difficult for patients to afford their medications.
These claims have been consolidated in an insulin class action lawsuit or multidistrict litigation (MDL) that is currently pending in the U.S. District Court of New Jersey.
Get Help Joining the Insulin Pricing Litigation
At Sokolove Law, we’re dedicated to helping state and local governments, as well as companies providing drug coverage to their employees, take action against corporations that prioritize profits over people.
Our team understands the impact that inflated insulin prices can have on communities, and we’re prepared to seek justice for those affected.
Why choose Sokolove Law?
- Over 45 years of experience holding powerful corporations accountable
- Nationwide presence with offices in nearly every state
- More than $9.6 Billion secured for our clients
Patients shouldn’t have to go without essential medications while corporations continue to profit.
Call (800) 995-1212 now or get a free case review to see if we can help you fight back with an insulin overpricing lawsuit.
Insulin PBM Lawsuit FAQs
What is the lawsuit about insulin?
The insulin lawsuit claims pharmacy benefit managers (PBMs) and drug manufacturers unfairly raised the price of insulin to maximize their profits.
This has left many patients unable to afford their diabetes medication, with more than 26% of patients claiming they took less than the prescribed amount of insulin to save on costs.
Is there an insulin price class action lawsuit?
Over 75 claims are currently pending in the insulin price class action lawsuit or multidistrict litigation, alleging that drug manufacturers and PBMs artificially inflated the cost of insulin drugs.
The lawsuit aims to hold PBMs accountable for their role in this pricing crisis and seek justice for those affected.
